Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT03755726 |
| Other study ID # |
CHPAU2018/01 |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
September 20, 2019 |
| Est. completion date |
September 20, 2029 |
Study information
| Verified date |
August 2022 |
| Source |
Centre Hospitalier de PAU |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
This registry aims to provide the first prospective, multicentric database of patients with
malignant hypertension. It will allow to assess modern epidemiology of the disease, diversity
of current management and care pathway, to deepen our pathophysiological knowledges, to
modernize the definition of this form of hypertension and its diagnostic criteria. The
network that will emerge will finally lead to the opportunity of setting up therapeutic
trials and establishing recommendations based on solid scientific evidence.
Description:
Malignant hypertension is the most severe form of high blood pressure, fatal if left
untreated. It has not disappeared, with an increasing incidence. Patients with the disease,
mainly young (35 to 55 years of age), have an unfavorable cardiovascular prognosis (14% of
cardiovascular and renal events at 4 years). Despite these facts, scientific research on the
subject remains limited. The definitions and diagnostic criteria have not changed since 1929,
and the therapeutic recommendations remain empirical.
This first prospective and multicentric registry will increase and modernize the knowledge of
the disease. From these data, diagnostic and therapeutic recommendations based on solid
scientific evidence could be developed.
The investigators want to first recruit 500 patients and define their prognosis at 5 years.
The impact of the patient's phenotype, type and number of target organs affected will be
studied.
A modern definition, adapted to these results, could be proposed. The epidemiology of the
disease, the care pathways, the target organ disorders and the management carried out in the
centers will be described in detail.
